• ω-Agatoxin IVA and Excitotoxicity

  2026-09-11

  The 1996 study tested whether blocking P- and Q-type calcium channels with ω-agatoxin IVA could reduce excitotoxic injury in cortical neuron-enriched cultures. Its central finding was negative but important: inhibition of toxin-sensitive calcium channels did not protect cells from veratridine-, ouabain-, or NMDA-induced injury under the tested conditions, cautioning against equating reduced glutamate release with neuroprotection.

• Propidium Iodide Workflows for Cell Analysis

  2026-09-11

  Propidium iodide converts membrane damage and DNA content into measurable red fluorescence for cell viability assay, apoptosis detection, and cell cycle analysis workflows. This guide connects practical PI staining with the reference study on ATR inhibition and ALT-positive cancer cells, helping researchers separate genuine drug effects from cell-line and handling artifacts.

• EMD638683: SGK1 Inhibitor Research Workflows

  2026-09-10

  EMD638683 enables time-controlled SGK pathway interrogation across endothelial stiffness, sodium-channel signaling, NDRG1 phosphorylation, and tumor-cell stress models. This workflow-focused guide covers formulation, assay design, comparative controls, and troubleshooting for vascular, hypertension, and cancer research.

• IBDV VP3 Disrupts IRF7 Antiviral Signaling

  2026-09-10

  The reference study identifies IBDV VP3 as a viral factor that suppresses chicken IRF7-mediated type I interferon responses by promoting proteasome-associated IRF7 loss. Its combination of viral strain comparison, IRF7 perturbation, pathway inhibition, and VP3 interaction analysis provides a useful framework for studying immune evasion through host protein stability.

• Angiotensin (1-7): A Smarter Assay Strategy

  2026-09-09

  Angiotensin (1-7) research is moving beyond receptor pharmacology toward sequence-resolved binding and pathway assays. This guide connects Mas receptor biology, peptide handling, and the 2025 spike–receptor study to improve experimental design and interpretation.

• Filipin III for Reliable Membrane Cholesterol Imaging

  2026-09-09

  This scenario-driven guide explains how Filipin III, SKU B6034, supports cholesterol detection in membranes without being mistaken for a direct viability assay. It covers experimental design, handling at −20°C and 37°C, controls, interpretation, and practical vendor selection for biomedical laboratories.

• 5-hme-dCTP and the Context of 5hmC

  2026-09-08

  A translational perspective on how 5-hme-dCTP supports mechanistic 5hmC research, assay validation, and plant drought-response studies while keeping genomic context and analytical limitations in view.

• Amikacin disulfate: Applied Research Workflows

  2026-09-07

  Build more informative antibacterial and protein-binding experiments with Amikacin disulfate, a semisynthetic aminoglycoside antibiotic suited to mechanism, ribosomal interaction, and resistance studies. A multimodal workflow helps separate 16S rRNA-dependent activity from protein complexation and assay interference.

• ROS-Degradable LNPs for Tumor-Selective mRNA Delivery

  2026-09-07

  Cai and colleagues developed a combinatorial library of thioketal-containing, ROS-degradable lipids to improve the preferential delivery of mRNA into tumor cells. The lead lipid, BAmP-TK-12, delivered DUF5-encoding mRNA, depleted mutant RAS, and produced stronger antitumor effects than a small-molecule RAS inhibitor in the reported experimental models.

• Marein Restores Mitoxantrone Sensitivity via ABCG2

  2026-09-05

  The reference study identifies marein, a flavonoid from Coreopsis tinctoria, as a competitive inhibitor of the ABCG2 drug-efflux transporter. By increasing intracellular exposure to ABCG2 substrate drugs, including Mitoxantrone, marein restored drug sensitivity in resistant cancer-cell models and highlighted F439 as an important interaction site.

• ARv7 and EPI-001 in Triple-Negative Breast Cancer

  2026-09-05

  This 2025 study links androgen receptor (AR) and AR variant 7 (ARv7) expression with adverse outcomes in triple-negative breast cancer and examines how Enzalutamide and EPI-001 affect metastatic and epithelial-to-mesenchymal transition biology. Its combination of patient immunohistochemistry, TCGA analysis, wound-healing assays, and molecular measurements highlights ARv7 localization and N-terminal targeting as useful research variables.

• α-Amanitin for RNA Polymerase II Assays

  2026-09-04

  α-Amanitin provides a focused way to interrogate RNA polymerase II-dependent transcription, from cultured-cell gene expression experiments to oocyte chromatin remodeling and embryo development models. This guide converts its mechanism into practical assay workflows, control strategies, and troubleshooting decisions.

• AO/PI Double Staining Kit: Practical Workflow

  2026-09-04

  The AO/PI Double Staining Kit provides a rapid fluorescent cell staining approach for separating viable, apoptotic, and membrane-compromised cell populations in one assay. It is suitable for screening and microscopy-based cell viability workflows, but staining alone should not be treated as definitive proof of a specific death mechanism or used without instrument- and cell-type-specific validation.

• mCherry mRNA for Better Redox Biosensor Assays

  2026-09-03

  mCherry mRNA can serve as more than a fluorescent marker: it can function as a transient delivery and translation control within complex cell assays. This article connects Cap 1 chemistry and modified nucleotides with practical lessons from a bacterial NADH/NAD+ biosensor study.

• TG003 Cdc2-Like Kinase Inhibitor Guide

  2026-09-02

  TG003 is a Cdc2-like kinase inhibitor that preferentially targets Clk1, Clk2, and Clk4 and modulates serine/arginine-rich protein phosphorylation. Its strongest research applications are alternative splicing modulation, splice site selection research, and mechanistic studies connecting CLK2 signaling with platinum resistance.

8561 records 1/571 page Next 12345 下5页 Last page